Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.University researchers discover new cancer-fighting compounds
By combining molecular imaging techniques with human cancer cell culture and animal model approaches, the researchers were able to reveal the ability of the compounds to kill human
By combining molecular imaging techniques with human cancer cell culture and animal model approaches, the researchers were able to reveal the ability of the compounds to kill human
Researchers at L’Aquila University in Italy conducted a comparative analysis by supplementing 86 patients with severe chronic venous insufficiency (CVI) with Pycnogenol and Daflon, a combination of diosmin
The phase II trial will test different vaccine dosages and schedules in 400 healthy volunteers between the ages of 18 and 55. The clinical trial is underway and
The multi-centered, placebo-controlled, parallel group trial was undertaken to establish formal dose response data of Fentanyl Taifun, with primary efficacy endpoints being the time to significant pain relief
ATI-7505, indicated for the treatment of gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and gastroparesis (delayed emptying of the stomach), is an oral, serotonin type 4 (5HT4)
Bayer has been acquiring shares in Schering at E89 per share in a takeover deal worth E17 billion. Bayer said that the next step in the integration of
Curis said that recent results from the study showed that the formulation did not downregulate the targeted pharmacodynamic marker in this tumor, suggesting that the drug candidate may
According to the American Academy of Dermatology, moisturizing and cleansing are crucial to treating atopic dermatitis, yet 23% of adults with eczema do not use a moisturizer to
According to the company, preclinical research into this combination offers compelling evidence for entering clinical trials, largely because IL-21 (Interleukin 21) appears to enhance a principal mechanism by
The company is attempting to gain approval for satraplatin in combination with prednisone as a second-line chemotherapy treatment for patients with hormone-refractory prostate cancer (HRPC). Satraplatin for this